Business
PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate
PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate ...
About this update from Pharmacielo Ltd.
[{"type":"text","content":"\n \n \n \n PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Shipped to existing Customer with operations in the U.K. and the E.U.\n \n \n THC-free broad-spectrum distillate from a single cultivar is a superior core formulation for nutraceutical and cosmetic formulations\n \n \n PharmaCielo is among the few global producers that deliver broad-spectrum formulations produced from specially selected, developed and standardized cultivars to B2B customers at consistently high quality and commercial scale.\n \n \n \n \n TORONTO\n \n and RIONEGRO,\n \n Colombia\n \n ,\n \n Feb. 18, 2021\n \n /CNW/ -\n \n PharmaCielo Ltd.\n \n (\"\n \n PharmaCielo\n \n \" or the \"\n \n Company\n \n \") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of\n \n Colombia's\n \n premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is pleased to announce that it has exported its first commercial shipment of THC-free broad-spectrum distillate to an existing customer with operations in the U.K. and the E.U. (the \"Customer\"). This higher-grade, higher-value extract delivery succeeds\n \n earlier shipments of 1,000Kg of CBD isolate PharmaCielo exported to this Customer\n \n in Q4-2020. This shipment of the broad-spectrum distillate marks PharmaCielo's inaugural delivery of a new product out of its extended product portfolio (\n \n announced in late 2020\n \n ) and complements earlier exports of the Company's CBD isolate to the U.K., the U.S.,\n \n Switzerland\n \n and other E.U. markets.\n \n \n \n \n \n \n \n \n \n \n \n Henning von Koss\n \n , CEO of PharmaCielo\n \n , commented, \"At PharmaCielo we believe that the industry will continue evolving towards the use of superior Active Pharmaceutical Ingredients such as full- and broad-spectrum extracts in favour of isolates. We have invested significant research behind our various cultivars, and each has been chosen and developed for different uses in the industry as it ev...